Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk-based super materials, has appointed Dr. Xiaoli Zhang as Director of Molecular Biology. Dr. Zhang, recognized for her groundbreaking work in spider silk and transgenic silkworms research, has already achieved significant breakthroughs in developing new spider silk-based fibers with enhanced capabilities.
The appointment strengthens the company's R&D capabilities as it accelerates the transition from laboratory development to large-scale commercialization of these revolutionary materials. Dr. Zhang's expertise in genetic engineering and bioengineering, backed by peer-reviewed publications, has been important in optimizing the company's genetic engineering of silkworms for spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured four registered trademarks for its SpydaSilk® brand, marking a significant milestone in its commercialization strategy for recombinant spider silk technology. SpydaSilk®, a Singapore-based joint venture founded in 2021, serves as a direct-to-consumer marketing channel for the company's spider silk materials.
The company is pursuing a dual-track approach by developing SpydaSilk® as a standalone brand while seeking collaborations with industry leaders in luxury fashion and high-performance apparel. Kraig Labs' proprietary recombinant spider silk fibers combine strength, elasticity, and softness, targeting high-value applications.
With recent production expansion, the company focuses on optimizing spider silk output and finalizing product designs for commercialization, aiming to accelerate technology adoption and drive revenue growth through this blended strategy.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a groundbreaking scientific milestone by successfully engineering the largest known spider silk gene insert into silkworm, nearly doubling the previous record. This breakthrough, led by Research Manager Dr. Xiaoli Zhang, enables the creation of larger, more complex proteins with unique mechanical properties for incorporation into silk fibers.
The achievement represents a significant advancement in developing high-performance biomaterials with enhanced strength, flexibility, and performance potential. While focusing on this innovation, the company maintains its commitment to commercializing its current recombinant spider silk production strains for applications in performance textiles, defense, and industrial sectors.
The company emphasizes that the significance lies not in the size of the genetic insert but in the information it carries, potentially unlocking new possibilities in material performance. Kraig Labs continues to pursue a dual strategy of commercializing existing spider silk technology while investing in future innovations.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk manufacturing, has established production operations in Lam Dong Province, Vietnam's premier silk-producing region. This achievement follows the January 2025 issuance of a new Investment Registration Certificate (IRC), which was important for the company's expansion plans.
The establishment in Lam Dong Province represents the fulfillment of a decade-long strategic goal and positions the company to accelerate its production growth. The Department of Finance in Lam Dong has officially confirmed Kraig Labs' presence in the region, enabling the company to strengthen its supply chain and scale up its proprietary spider silk production.
CEO Kim Thompson described this development as a 'transformative moment' for the company, emphasizing their commitment to making significant investments to drive production to unprecedented levels while contributing to Vietnam's silk sector development.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone in spider silk manufacturing. The company has completed its largest single batch of BAM-1 recombinant spider silk, surpassing its entire 2024 production output in just one production run in early 2025.
The achievement follows a record-breaking 2024, where the company produced more spider silk than all previous years combined. This expansion demonstrates Kraig Labs' ability to scale up commercial production of its revolutionary spider silk technology for applications in technical textiles, defense, and performance apparel industries.
According to COO Jon Rice, this milestone validates the company's robust spider silk production platform and its capability to deliver industrial-scale quantities of this advanced biomaterial. The company aims to meet what it perceives as substantial global demand for high-performance spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a significant breakthrough in its genetic research program, successfully doubling the complexity and size of its spider silk gene insert package. This advancement aims to enhance the performance characteristics of their spider silk fibers, including strength, elasticity, and durability.
The company is pursuing a dual strategy: advancing research while maintaining focus on commercial production. CEO Kim Thompson emphasizes the potential of larger gene insert packages to unlock superior material characteristics, while COO Jon Rice confirms they remain on track for commercial-scale manufacturing and material sales this year.
The breakthrough is expected to impact applications across technical textiles, defense, and medical industries. Kraig Labs continues to position itself as a global leader in spider silk technology, balancing innovation with production to meet market demand for these bioengineered materials.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a breakthrough in engineered fibers with the successful creation of a new silk based on caddisfly silk proteins. This innovation leverages the unique underwater adhesive properties of caddisfly silk, known for its ability to maintain durability when submerged.
The new transgenic fiber, developed through the company's proprietary silkworm-based production system, opens possibilities in various applications including medical adhesives, biomedical textiles, performance apparel, and next-generation fiber technologies. The company has filed a provisional utility patent for this technology.
This development represents an expansion beyond spider silk proteins and demonstrates the company's capability to engineer materials combining different silk proteins' properties. The breakthrough aims to create super materials with enhanced strength, elasticity, and functionality, positioning Kraig Labs at the forefront of biotechnological innovation in sustainable, high-performance materials.
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a new investment license in Vietnam, marking a significant milestone in its expansion strategy. This authorization enables the company to scale up its production operations to meet growing demand for its spider silk-based fibers.
The expansion will enhance Kraig Labs' capacity to supply its innovative materials to various markets, including textiles, defense, and medical sectors. The company plans to develop advanced rearing facilities in Vietnam, focusing on environmentally sustainable practices while producing strong, lightweight, and eco-friendly materials.
CEO Kim Thompson emphasized that this license demonstrates confidence in their technology and positions them to expand their production footprint, making cost-effective spider silk production a reality.
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a $10 million standby equity purchase agreement (SEPA) with YA II PN, (Yorkville) to support its spider silk production expansion and commercialization efforts. The agreement provides flexible access to capital over the next 36 months, with no minimum use requirements or operational restrictions.
The SEPA is designed to help bridge the company's transition to revenue generation, allowing Kraig Labs to strategically access funds for building production capacity, developing spider silk inventory, creating new consumer products, and establishing sales partnerships. The company maintains full discretion over if and when to utilize this funding.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a breakthrough in spider silk technology with the successful creation of a new transgenic inspired by the Darwin's bark spider. The company has integrated key genetic sequences from the Darwin's bark spider, known for producing the toughest biological material ever measured (10 times tougher than para-aramid fibers used in bulletproof vests), into their proprietary silkworms.
This development combines the exceptional properties of Darwin's bark spider silk with traditional silkworm silk production efficiency, targeting applications in textile, defense, medical, and industrial sectors. The company's COO, Jon Rice, indicated that this breakthrough is one of many recent achievements, with expectations for continued developments in 2025 alongside metric ton production of existing hybrids.